Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Article Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Team
    • Feedback
    • Reprints
    • Impact Factor
    • Editorial Fellowship Application Process
  • ASN Kidney News
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Article Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Team
    • Feedback
    • Reprints
    • Impact Factor
    • Editorial Fellowship Application Process
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
Epidemiology and Outcomes
You have accessRestricted Access

Incidental Renal Artery Stenosis Is an Independent Predictor of Mortality in Patients with Peripheral Vascular Disease

Kwok-Wai Mui, Mengalvio Sleeswijk, Huib van den Hout, Jef van Baal, Gerjan Navis and Arend-Jan Woittiez
JASN July 2006, 17 (7) 2069-2074; DOI: https://doi.org/10.1681/ASN.2005080827
Kwok-Wai Mui
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mengalvio Sleeswijk
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Huib van den Hout
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jef van Baal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerjan Navis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arend-Jan Woittiez
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

Abstract

In patients with peripheral vascular disease (PVD), mortality is high and renal artery stenosis (RAS) is a frequent incidental finding. RAS carries a high risk for mortality, but whether incidentally discovered RAS is a risk factor for mortality is unknown. The prognostic impact of incidental RAS for mortality was studied in 550 consecutive patients who underwent intra-arterial digital subtraction angiography for PVD in a single center between 1997 and 2000. In 491 patients (336 men, 155 women; mean follow-up 3.8 ± 1.9 yr), the renal arteries were visualized and follow-up data were available. RAS (diameter reduction >50%) was present in 26% of the patients. Mortality in the RAS group was 59 versus 28% in the non-RAS group (odds ratio 3.8; 95% confidence interval 2.5 to 5.7; P < 0.0001). Diabetes, previous myocardial infarction, history of PVD, stroke, and hypertension were more frequent in the RAS group; age was higher and GFR was lower in the RAS group. Therefore, RAS was associated with elevated mortality and increased prevalence of cardiovascular risk factors. Cox regression analysis showed that RAS was an independent predictor for mortality (P = 0.005), along with age, diabetes, smoking, previous myocardial infarction, history of PVD, and stroke. In patients who were evaluated for PVD by digital subtraction angiography, mortality was high. Incidental RAS was a frequent finding and an independent predictor for mortality. Whether RAS is a marker for or, alternatively, a mediator of the poor prognosis and whether prognosis can be improved by specific intervention should be the subject of future prospective studies.

In patients with peripheral vascular disease (PVD), mortality is high (1–4); this is likely to be due to the clustering of cardiovascular risk factors in these patients. When renal function impairment is present simultaneously, mortality is even higher (5). Renal artery stenosis (RAS) is encountered frequently as an incidental finding in patients who undergo routine angiography for PVD, with a prevalence between 5 and 40% (6–8). This corresponds to the high prevalence of RAS (5 to 20%) in patients who undergo routine coronary angiography (9,10). Atherosclerotic RAS is associated not only with hypertension, ischemic nephropathy, and cardiovascular disease (11,12) but also with a considerably increased mortality (13–15). The impact of RAS as a risk factor for mortality was established mainly in patients who underwent a diagnostic work-up for hypertension and/or renal failure. Data in patients who underwent diagnostic cardiac catheterization simultaneously with an aortography (9,10) showed that incidental RAS can be an independent risk factor for mortality. Whether this holds also true for incidental RAS in PVD has not been established so far. We therefore investigated the prognostic impact of incidental RAS for mortality in consecutive patients who underwent intra-arterial digital subtraction angiography (DSA) for PVD in a single center between 1997 and 2000.

Materials and Methods

We reviewed a cohort of 550 consecutive patients who had clinically confirmed PVD by noninvasive examinations (ankle-brachial index or duplex Doppler of the lower extremities) and underwent angiography with the intention of surgical or radiologic intervention from January 1997 to December 2000 in a single center, as judged by the vascular surgeons. Patients in whom the angiogram did not allow proper assessment of the renal arteries were excluded from the analysis. A single reviewer, who was blinded to patients’ diagnoses and indications for the procedure, evaluated the angiograms for RAS. A diameter reduction of >50% was considered diagnostic for presence of RAS; severe stenosis was considered to be present when the stenosis exceeded 75% (10). Clinical data were obtained from patient records, and mortality data were obtained from the hospital information system.

Definitions

Hypertension was defined according to the 2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension (16,17), prescription of antihypertensive medications, or a clinical history of hypertension. A patient was classified as having diabetes when there was a clinical history of diabetes or when the patient was taking insulin or oral antidiabetic agents. We used the abbreviated Modification of Diet in Renal Disease equation advocated in the Kidney Disease Outcomes Quality Initiative guidelines (18) to estimate GFR. These data are presented in this article. In addition, we estimated GFR by the quadratic equation proposed by Rule et al. (19), because this equation is assumed to provide a better estimate of renal function in patients in whom renal function is normal or only mildly impaired. All analyses also were performed using estimated GFR by the latter equation; this did not alter the results (data not shown).

Baseline Characteristics

Eight clinical variables were recorded at baseline (i.e., time of angiography): Serum creatinine before angiography, history of myocardial infarction, history of stroke, diabetes (present or absent), smoking history (ever/stopped or never), history of previous PVD (i.e., previous treatment either conservative or not otherwise specified), history of hypertension, and current BP at time of angiography.

Statistical Analyses

Comparisons between groups (RAS versus non-RAS) on baseline variables were done using χ2 test. Survival was assessed by Kaplan-Meier curves, and to test for independent predictors of mortality, we performed multivariate analysis using single-step Cox regression analysis. The renal function was classified according to the cutoffs recommended in the Kidney Disease Outcomes Quality Initiative criteria (18) for defining moderate (GFR 30 to 60 ml/min per 1.73 m2) and severe (GFR <30 ml/min per 1.73 m2) renal function impairment. All statistical analyses were performed in SPSS 12.0 for Windows. Statistical significance was defined as P < 0.05.

Results

From January 1997 to December 2000, 550 consecutive angiograms were performed in patients with confirmed PVD. The renal arteries could be assessed in their entirety for RAS (diameter reduction >50% to 75% and ≥75%) in 499 angiograms. The reasons for incomplete visualization of the renal arteries were technical. Of the 499 assessable patients, eight could not be included because of incomplete clinical data. Atherosclerotic RAS was present in 129 (26%) of the 491 patients; of these patients, 35 (27%) had a luminal RAS of >75%, and 74 (57%) had a bilateral RAS.

Baseline characteristics of the population are presented in Table 1 and were divided according to the presence or absence of RAS. Patients with RAS were significantly older and their mortality was significantly higher than in patients without RAS (59 and 28%, respectively; P < 0.0001). In patients with RAS, the prevalence of several cardiovascular risk factors (hypertension, diabetes, previous history of PVD, myocardial infarction, and stroke) was higher than in patients without RAS, but the proportion of smokers, remarkably, was lower in the group with RAS. As shown by the Kaplan-Meier survival curves in Figure 1, the estimated 5-yr survival probability was 37% for patients with RAS as compared with 72% for patients without RAS (odds ratio 3.76). Patients with moderate and severe renal function impairment were overrepresented among the patients with RAS as compared with the group without RAS (Table 2). Among patients with RAS ≥75%, the majority had moderate or severe renal function impairment, whereas this amounted to approximately one third of the patients with RAS <75% (Table 2). Mean GFR was 67.2 ± 25.4 ml/min for RAS <75% versus 54.8 ± 26.4 ml/min for RAS ≥75% (P = 0.016). Therefore, RAS and its severity are associated with the severity of renal function impairment. The association of renal function and unilateral RAS versus bilateral RAS was NS (data not shown).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Kaplan-Meier survival plots for 491 patients with peripheral vascular disease (PVD), comparing outcome for those without renal artery stenosis (NRAS) and with renal artery stenosis (RAS).

View this table:
  • View inline
  • View popup
Table 1.

Characteristics of patients with and without RASa

View this table:
  • View inline
  • View popup
Table 2.

Distribution of baseline GFR according to the presence or absence of RAS and the severity of RAS

The crude mortality rates by absence or presence and severity of RAS is given in Table 3, showing significant effects of presence and severity of RAS on mortality, both for the population as a whole and after stratification of GFR in each of the various strata of GFR, i.e., normal to mildly impaired renal function (GFR >60 ml/min), moderately impaired renal function (GFR 30 to 60 ml/min), and severely impaired renal function (GFR <30 ml/min). Mortality was particularly high in patients with moderate and severe renal function impairment. Time-dependent survival by presence or absence of RAS and by stratum of renal function is shown as Kaplan-Meier curves in Figure 2. It shows that RAS and GFR <60 ml/min both were associated with worse survival, with the poorest survival in patients with both RAS and GFR <60 ml/min (overall log rank test χ2 P < 0.0001; group 1 versus group 2 P = 0.0025, relative risk [RR] 1.89, 95% confidence interval [CI] 1.31 to 3.49; group 3 versus group 1 P < 0.0001, RR 2.44, 95% CI 1.92 to 5.41; group 4 versus group 1 P < 0.0001, RR 4.61, 95% CI 2.92 to 22.8).

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Kaplan-Meier survival plots for patients with PVD and GFR >60 ml/min per 1.73 m2 and GFR <60 ml/min per 1.73 m2, comparing outcome for those without RAS and with RAS.

View this table:
  • View inline
  • View popup
Table 3.

Overall mortality and distribution of GFR according to presence or absence of RAS and severity of RAS

The independent contribution of the various risk factors for mortality was assessed by Cox regression analysis, as shown in Table 4. It shows first the crude model, in which the widely known cardiovascular risk factors age, diabetes, history of previous PVD, smoking, previous myocardial infarction, and previous stroke were independent predictors for mortality. The contribution of stratum of renal function reached significance only for GFR <30 ml/min (P = 0.047). When the model was adjusted for presence of RAS, the contribution of class of renal function was attenuated, whereas RAS was an independent predictor for mortality (P = 0.005).

View this table:
  • View inline
  • View popup
Table 4.

Single-step Cox multivariate analysis of the predictors of mortalitya

Discussion

Our data confirm that incidental RAS is a frequent finding in patients who are evaluated for PVD by DSA. The main finding of our study is that we demonstrated, for the first time, that RAS is an independent predictor of mortality in this population. Moreover, we found that incidental RAS was closely associated with the level of renal function. Remarkably, the prognostic impact of incidental RAS was true both in patients with normal or mild renal function impairment and in patients with moderate to severe renal insufficiency.

The prevalence of incidental atherosclerotic RAS in our population was 26%, which is well within the range observed in other studies on PVD, in which prevalences ranged from 5 to 40% (6–8). Prevalence obviously can be confounded by the definition used; our definition of RAS (a 50% reduction in renal artery lumen) is in line with similar studies on survival in coronary artery disease (9,10), and our cutoff for severe stenosis (≥75% luminal narrowing) is in accordance with the study described by Conlon et al. (10).

In patients with PVD, mortality is high. McKenna et al. (1) found a 5-yr survival of 44% in patients with PVD (as demonstrated by an ankle-brachial index of <0.4) versus an 85% survival in patients without vascular disease. Criqui et al. (2) reported a 5-yr survival of 70% in patients with symptomatic PVD versus 90% in normal individuals. When renal insufficiency was present concomitantly, mortality was even higher, with a 1-yr survival rate of 56% for patients with a GFR <30 ml/min per 1.73 m2 compared with 83% for patients with a GFR >60 ml/min per 1.73 m2 (5). The overall mortality in our patients is in line with these studies, but our data also show that the subgroup with RAS has a prognosis that is considerably worse. Also, in patients with symptomatic RAS, mortality is increased, but the reported mortality rates are lower than in our patients with RAS. Isles et al. (14) reported a 5-yr survival probability of 83% for patients with renovascular hypertension, and Wollenweber et al. (13) found a 5-yr survival of 67% for patients with atherosclerotic renovascular disease versus 90% for the general population. A more recent study by Wright et al. (15) showed a mortality rate of 35.7% for patients with atherosclerotic renovascular disease using a mean follow-up of 27.7 mo. Whereas a direct comparison is not warranted, our data nevertheless suggest that incidental RAS in patients with PVD carries a particularly poor prognosis, especially in patients with moderate to severe renal failure (of whatever cause).

What would be the implications of our findings? First, our study is the first to allow for mutual association among RAS, renal function impairment, and mortality in patients with PVD. These data may provide a potential pathogenic link between the association of PVD and renal insufficiency (20) and the association between renal function impairment and increased mortality in patients with PVD as described by O’Hare et al. (5), respectively. Our data suggest that a considerable proportion of the presence of renal function impairment in PVD can be ascribed to the presence of RAS but do not allow a conclusive dissection as to which of the two is the main causal factor for mortality. It is remarkable in this respect that adjustment for RAS attenuated the impact of renal function in the multivariate model, but considering their close association, it presumably would be overly artificial to attempt to disentangle their respective impact, so whether RAS is an independent causal factor remains hypothetical. In principle, RAS in itself can exert deleterious pathophysiologic effects by excess production of angiotensin II (21), which is a potent vasoconstrictor that has been implicated in the activation of cell proliferation systems (22). High levels of angiotensin II are associated with left ventricular hypertrophy, endothelial dysfunction, and target organ damage (23). This pathway could explain, at least partially, the increased mortality in symptomatic atherosclerotic RAS. If this would be the case, then it would be logical to assume that pharmacologic blockade of the renin-angiotensin aldosterone system might have the potential to ameliorate the poor prognosis, but obviously this assumption would need empirical substantiation.

Second, our data suggest that incidentally found RAS can serve as a marker of a poor prognosis. When RAS is present, it is a strong marker of extended cardiovascular disease as suggested by the well-established clinical predictors of incidental RAS. Therefore, it could well be a marker of more extended coronary or cerebrovascular disease and thus related to increased mortality. In this perspective, it has been shown that in patients who undergo diagnostic cardiac catheterization simultaneously with an aortography, incidental RAS was an independent risk factor for mortality (9,10). Moreover, the severity of RAS was related to mortality. In our study, however, no appropriate characterization of coronary or cerebrovascular disease was available, because the patients all were referred to the hospital by the general practitioner because of suspicion of PVD and were evaluated and treated by the vascular surgeon only. Therefore, a possible relationship between RAS and its severity and coronary artery disease cannot be made for our population.

As anticipated, several well-established clinical predictors of incidental RAS, namely older age (24–26), hypertension (24,25,27,28), impaired renal function (24,28), a history of coronary artery disease (9,10,24,26), and diabetes (25,27,28) were more prevalent in our group with RAS, with the exception, however, of a history of smoking (25,27). This seeming discrepancy may be due to bias by indication, because the patients with RAS were older and had more symptomatic comorbidity and therefore were more likely to have received previous advice to stop smoking. Whereas the difference in prevalence of risk factors may have contributed to the overall difference in mortality, the Cox regression analysis demonstrated the independent contribution of RAS.

The clinical implications of incidentally discovered RAS so far are uncertain. Studies on its natural history (6,15,29,30) reported that progression to end-stage renal failure is rare (6,7). From the perspective of preservation of renal function, therefore, revascularization is not recommended for patients with incidentally discovered RAS (6,7). It may be worthwhile to refer these patients to the internist or cardiologist for a thorough screening for cardiovascular disease and for aggressive cardiovascular preventive therapy. It is known that aggressive treatment of hypertension and strict regulation of diabetes improve cardiovascular morbidity and mortality (31–33) and that an intensive lipid-lowering statin regimen can improve prognosis in high-risk populations (34).

Some limitations of our study should be considered. Because this was a retrospective post hoc analysis, we were not able to evaluate all the renal arteries in the patients. In addition, all but eight patients were included in the follow-up. Unfortunately, the specific number of deaths as a result of cardiovascular problems is not known because cause of death was not specified in our patient data and our hospital information system was not linked to a national registry for death registration. All the angiograms were performed in the same center; as a result, it may influence the generalizability of our findings. However, all angiograms were analyzed by the same radiologist, who was blinded to patient diagnosis and indications, so there were no interobserver variances. In the patient records, it was remarkable that hardly any of these patients were under medical supervision by an internist or a nephrologist. This may be because all our patients described were referred by general practitioners to the vascular surgeon. Our patients, therefore, may well be representative for those who are referred for angiography for evaluation for PVD. However, it may not be representative for the whole PVD population, because it is known that many patients with PVD go unrecognized in general practice (35).

Conclusion

Incidental RAS is a frequent finding in patients who are evaluated for PVD by DSA, and this finding predicts mortality independent of other risk factors. Therefore, risk assessment in patients who undergo angiography for PVD could be improved by consideration of the renal arteries. Future prospective studies should examine whether RAS is a marker or mediator of poor prognosis and whether prognosis can be improved by specific intervention or medical therapy.

Acknowledgments

We thank Dr. C.A. Stegeman for expert help data analysis and R. Balena for the data collection.

Footnotes

  • Published online ahead of print. Publication date available at www.jasn.org.

  • © 2006 American Society of Nephrology

References

  1. ↵
    McKenna M, Wolfson S, Kuller L: The ratio of ankle and arm arterial pressure as an independent predictor of mortality. Atherosclerosis 87: 119–128, 1991
    OpenUrlCrossRefPubMed
  2. ↵
    Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, Browner D: Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 326: 381–386, 1992
    OpenUrlCrossRefPubMed
  3. Bowlin SJ, Medalie JH, Flocke SA, Zyzanski SJ, Yaari S, Goldbourt U: Intermittent claudication in 8343 men and 21-year specific mortality follow-up. Ann Epidemiol 7: 180–187, 1997
    OpenUrlCrossRefPubMed
  4. ↵
    Muluk SC, Muluk VS, Kelley ME, Whittle JC, Tierney JA, Webster MW, Makaroun MS: Outcome events in patients with claudication: A 15-year study in 2777 patients. J Vasc Surg 33: 251–257, 2001
    OpenUrlCrossRefPubMed
  5. ↵
    O’Hare AM, Bertenthal D, Shlipak MG, Sen S, Chren MM: Impact of renal insufficiency on mortality in advanced lower extremity peripheral arterial disease. J Am Soc Nephrol 16: 514–519, 2005
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Iglesias JI, Hamburger RJ, Feldman L, Kaufman JS: The natural history of incidental renal artery stenosis in patients with aortoiliac vascular disease. Am J Med 109: 642–647, 2000
    OpenUrlCrossRefPubMed
  7. ↵
    Leertouwer TC, Pattynama PM, van den Berg-Huysmans A: Incidental renal artery stenosis in peripheral vascular disease: A case for treatment? Kidney Int 59: 1480–1483, 2001
    OpenUrlCrossRefPubMed
  8. ↵
    Pillay WR, Kan YM, Crinnion JN, Wolfe JH: Prospective multicentre study of the natural history of atherosclerotic renal artery stenosis in patients with peripheral vascular disease. Br J Surg 89: 737–740, 2002
    OpenUrlCrossRefPubMed
  9. ↵
    Conlon PJ, Athirakul K, Kovalik E, Schwab SJ, Crowley J, Stack R, McCants CB Jr, Mark DB, Bashore TM, Albers F: Survival in renal vascular disease. J Am Soc Nephrol 9: 252–256, 1998
    OpenUrlAbstract
  10. ↵
    Conlon PJ, Little MA, Pieper K, Mark DB: Severity of renal vascular disease predicts mortality in patients undergoing coronary angiography. Kidney Int 60: 1490–1497, 2001
    OpenUrlCrossRefPubMed
  11. ↵
    Kalra PA, Guo H, Kausz AT, Gilbertson DT, Liu J, Chen SC, Ishani A, Collins AJ, Foley RN: Atherosclerotic renovascular disease in United States patients aged 67 years or older: Risk factors, revascularization, and prognosis. Kidney Int 68: 293–301, 2005
    OpenUrlCrossRefPubMed
  12. ↵
    Wright JR, Shurrab AE, Cooper A, Kalra PR, Foley RN, Kalra PA: Left ventricular morphology and function in patients with atherosclerotic renovascular disease. J Am Soc Nephrol 16: 2746–2753, 2005
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Wollenweber J, Sheps SG, Davis GD: Clinical course of atherosclerotic renovascular disease. Am J Cardiol 21: 60–71, 1968
    OpenUrlCrossRefPubMed
  14. ↵
    Isles C, Main J, O’Connell J, Brown I, Findlay J, Stewart R, Wilkinson R: Survival associated with renovascular disease in Glasgow and Newcastle: A collaborative study. Scott Med J 35: 70–73, 1990
    OpenUrlPubMed
  15. ↵
    Wright JR, Shurrab AE, Cheung C, Waldek S, O’Donoghue DJ, Foley RN, Mamtora H, Kalra PA: A prospective study of the determinants of renal functional outcome and mortality in atherosclerotic renovascular disease. Am J Kidney Dis 39: 1153–1161, 2002
    OpenUrlCrossRefPubMed
  16. ↵
    Prichard BN, Vallance P: ESH/ESC guidelines. J Hypertens 22: 859–861, 2004
    OpenUrlCrossRefPubMed
  17. ↵
    Cifkova R, Erdine S, Fagard R, Farsang C, Heagerty AM, Kiowski W, Kjeldsen S, Luscher T, Mallion JM, Mancia G, Poulter N, Rahn KH, Rodicio JL, Ruilope LM, van ZP, Waeber B, Williams B, Zanchetti A: Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J Hypertens 21: 1779–1786, 2003
    OpenUrlCrossRefPubMed
  18. ↵
    K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 39: S1–S266, 2002
    OpenUrlCrossRefPubMed
  19. ↵
    Rule AD, Larson TS, Bergstralh EJ, Slezak JM, Jacobsen SJ, Cosio FG: Using serum creatinine to estimate glomerular filtration rate: Accuracy in good health and in chronic kidney disease. Ann Intern Med 141: 929–937, 2004
    OpenUrlCrossRefPubMed
  20. ↵
    O’Hare AM, Glidden DV, Fox CS, Hsu CY: High prevalence of peripheral arterial disease in persons with renal insufficiency: Results from the National Health and Nutrition Examination Survey 1999–2000. Circulation 109: 320–323, 2004
    OpenUrlAbstract/FREE Full Text
  21. ↵
    Jackson B, Franze L, Sumithran E, Johnston CI: Pharmacologic nephrectomy with chronic angiotensin converting enzyme inhibitor treatment in renovascular hypertension in the rat. J Lab Clin Med 115: 21–27, 1990
    OpenUrlPubMed
  22. ↵
    Daemen MJ, Lombardi DM, Bosman FT, Schwartz SM: Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res 68: 450–456, 1991
    OpenUrlAbstract/FREE Full Text
  23. ↵
    Mahmud A, Feely J: Arterial stiffness and the renin-angiotensin-aldosterone system. J Renin Angiotensin Aldosterone Syst 5: 102–108, 2004
    OpenUrlCrossRefPubMed
  24. ↵
    Valentine RJ, Clagett GP, Miller GL, Myers SI, Martin JD, Chervu A: The coronary risk of unsuspected renal artery stenosis. J Vasc Surg 18: 433–439, 1993
    OpenUrlCrossRefPubMed
  25. ↵
    Swartbol P, Thorvinger BO, Parsson H, Norgren L: Renal artery stenosis in patients with peripheral vascular disease and its correlation to hypertension. A retrospective study. Int Angiol 11: 195–199, 1992
    OpenUrlPubMed
  26. ↵
    Harding MB, Smith LR, Himmelstein SI, Harrison K, Phillips HR, Schwab SJ, Hermiller JB, Davidson CJ, Bashore TM: Renal artery stenosis: Prevalence and associated risk factors in patients undergoing routine cardiac catheterization. J Am Soc Nephrol 2: 1608–1616, 1992
    OpenUrlAbstract
  27. ↵
    Missouris CG, Buckenham T, Cappuccio FP, MacGregor GA: Renal artery stenosis: A common and important problem in patients with peripheral vascular disease. Am J Med 96: 10–14, 1994
    OpenUrlCrossRefPubMed
  28. ↵
    Olin JW, Melia M, Young JR, Graor RA, Risius B: Prevalence of atherosclerotic renal artery stenosis in patients with atherosclerosis elsewhere. Am J Med 88: 46N–51N, 1990
    OpenUrlCrossRefPubMed
  29. ↵
    Williamson WK, bou-Zamzam AM Jr, Moneta GL, Yeager RA, Edwards JM, Taylor LM Jr, Porter JM: Prophylactic repair of renal artery stenosis is not justified in patients who require infrarenal aortic reconstruction. J Vasc Surg 28: 14–20, 1998
    OpenUrlCrossRefPubMed
  30. ↵
    Tollefson DF, Ernst CB: Natural history of atherosclerotic renal artery stenosis associated with aortic disease. J Vasc Surg 14: 327–331, 1991
    OpenUrlCrossRefPubMed
  31. ↵
    Turnbull F: Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively-designed overviews of randomised trials. Lancet 362: 1527–1535, 2003
    OpenUrlCrossRefPubMed
  32. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 329: 977–986, 1993
    OpenUrlCrossRefPubMed
  33. ↵
    Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352: 837–853, 1998
    OpenUrlCrossRefPubMed
  34. ↵
    Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350: 1495–1504, 2004
    OpenUrlCrossRefPubMed
  35. ↵
    Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, Krook SH, Hunninghake DB, Comerota AJ, Walsh ME, McDermott MM, Hiatt WR: Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 286: 1317–1324, 2001
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology: 17 (7)
Journal of the American Society of Nephrology
Vol. 17, Issue 7
July 2006
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
Incidental Renal Artery Stenosis Is an Independent Predictor of Mortality in Patients with Peripheral Vascular Disease
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Incidental Renal Artery Stenosis Is an Independent Predictor of Mortality in Patients with Peripheral Vascular Disease
Kwok-Wai Mui, Mengalvio Sleeswijk, Huib van den Hout, Jef van Baal, Gerjan Navis, Arend-Jan Woittiez
JASN Jul 2006, 17 (7) 2069-2074; DOI: 10.1681/ASN.2005080827

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Incidental Renal Artery Stenosis Is an Independent Predictor of Mortality in Patients with Peripheral Vascular Disease
Kwok-Wai Mui, Mengalvio Sleeswijk, Huib van den Hout, Jef van Baal, Gerjan Navis, Arend-Jan Woittiez
JASN Jul 2006, 17 (7) 2069-2074; DOI: 10.1681/ASN.2005080827
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Conclusion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Survival among Patients with Kidney Failure in Jalisco, Mexico
  • A Population-Based, Prospective Study of Blood Pressure and Risk for End-Stage Renal Disease in China
  • Hepatitis C Virus and Death Risk in Hemodialysis Patients
Show more Epidemiology and Outcomes

Cited By...

  • Role of Renin-Angiotensin System Blockade in Atherosclerotic Renal Artery Stenosis and Renovascular Hypertension
  • Google Scholar

Similar Articles

Related Articles

  • This Month’s Highlights
  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe

© 2021 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire